OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...
Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...
Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...
Please provide your email address to receive an email when new articles are posted on . Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 ...
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...
Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results